Journals / Van Tıp Dergisi / 2015 / Cilt: 22 - Sayı: 3

Meme Kanseri için Verilen Kemoterapi Sonrası Gelişen Multipl Myelom: Vaka Takdimi ve Kısa Bir Derleme

Multiple Myeloma Emerging After Chemotherapy for Breast Cancer: Case Presentation and a Brief Review

Pages
194–196
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case we determined multiple myeloma after the administration of chemotherapy for breast cancer and there was not another etiologic factor except antineoplastic agent administration.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Breast cancer is the most common cancer of women.
📊
Key Findings & Data:Multiple myeloma is characterized by monoclonal proliferation of plasma cells.
💡
Conclusion & Impact:In this case we determined multiple myeloma after the administration of chemotherapy for breast cancer and there was not another etiologic factor except antineoplastic agent administration.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Breast cancer is the most common cancer of women. Multiple myeloma is characterized by monoclonal proliferation of plasma cells. There are malignancies secondary to chemotherapy and it has long been recognized. We describe a woman presented with breast cancer and after chemotherapy and radiotherapy she had achieved remission. Because of complaints about skeletal discomfort we reevaluated the patient and diagnosed multiple myeloma and decided to treat with chemotherapy and bone marrow transplantation. In this case we determined multiple myeloma after the administration of chemotherapy for breast cancer and there was not another etiologic factor except antineoplastic agent administration.

Özet

Meme kanseri kadınlarda en sık görülen kanser türüdür. Multipl myelom ise tek hücre tipi kökenli plazma hücrelerinin aşırı çoğalması karakterli bir hastalıktır. Literatürde kemoterapiye ikincil bir çok malignite bildirilmiştir. Sunduğumuz olguda kemoterapi ve radyoterapi sonrası remisyon sağlanmıştır. İskelet sistemi ile ilgili yakınmaları nedeniyle değerlendirilen olguya multipl myelom tanısı konup, ve kemik iliği nakli planlanmıştır. Bu olguyu meme kanseri nedeniyle verilen kemoterapi sonrasında multipl myelom tanısı konması ve antineoplastik ilaç uygulaması dışında başka herhangi bir etyolojik faktör saptanmaması nedeniyle sunmaktayız.

🔖

Cite This Article

GÜREL, A., AYGEN, B., KARA, M., TAMER, E. E. (2015). Meme Kanseri için Verilen Kemoterapi Sonrası Gelişen Multipl Myelom: Vaka Takdimi ve Kısa Bir Derleme. Van Tıp Dergisi, Cilt: 22 - Sayı: 3, 194–196. https://ajindex.com/articles/334054

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Sinn HP, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care (Basel) 2013; 8(2):149-154
  2. Bartsch R, Steger GG. Adjuvant chemotherapy in breast cancer. Memo 2008; 1:91-98
  3. Facts and Figures 2005. ACS 2005:9-11
  4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2):106-130
  5. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352(9132):930-942
  6. Grosbois B, Decaux O, Azais I, Facon T, AvetLoiseau H. Current treatment strategies for multiple myeloma. Eur J Intern Med 2002; 13(2):85-95
  7. Cömert M, Güneş AE, Sahin F, Saydam G. Quality of Life and Supportive Care in Multiple Myeloma. Turk J Haematol 2013; 30(3):234- 246
  8. Chang HJ, Lee JH, Do YR, Bae SH, Lee JL, Nam SH, et al. A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. Korean J Intern Med 2011; 26(4):403-409
  9. Tahan G, Ziauddin MF, Soran A. The role of high risk clinics in screening and managing breast cancer. J Breast Health 2009; 5:167-175
  10. Aranda E. Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. Clin Transl Oncol 2008; 10:552-559
  11. Öksüzoğlu ÖB. Meme Kanserinde Adjuvan Kemoterapi. Türkiye Klinikleri J Med OncolSpecial Topics 2012; 5(2):47-54
  12. Göksu SS, Coşkun HŞ. Meme Kanseri Tedavisinde Yeni İlaçlar. Türkiye Klinikleri J Med Oncol- Special Topics 2012; 5(2):121-127
  13. Marinopoulos S, Skorda L, Karatapanis S, Rasidakis A. Multiple myeloma emerging after chemotherapy for non-small cell lung cancer. Med Oncol 2008; 25:415-418
  14. Carli PM, Sgro C, Parchin-Geneste N, Isambert N, Mugneret F, Girodon F, et al. Increase therapy-related leukemia secondary to breast cancer. Leukemia 2000; 14(6):1014-1017
  15. Sonneveld P, Kurth KH, Hagemeyer A, Abels J. Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma. Cancer 1990; 65(1):23-25
  16. Wright JD, St Clair CM, Deutsch I, Burke WM, Gorrochurn P, Sun X, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 2010; 116(10):2486-2492
  17. Waller CF, Fetscher S, Lange W. Secondary chronic myelogenous leukemia after chemotherapy followed by adjuvant radiotherapy for small cell lung c